Pathologic responses to neoadjuvant chemoimmunotherapy in primary limited‐stage small‐cell lung cancer
Abstract Background Immunotherapy has been proved to have a large effect on extensive‐stage small cell lung cancer, but the role of immunotherapy in limited‐stage small‐cell lung cancer (LS‐SCLC) is still unknown. Methods A retrospective study of six patients with LS‐SCLC who were treated with neoad...
Main Authors: | Meng Lu, Ran Zhang, Li‐sha Qi, Ya‐lei Wang, Xiao‐xuan Sun, Jian You |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-11-01
|
Series: | Thoracic Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1111/1759-7714.14679 |
Similar Items
-
Neoadjuvant chemoimmunotherapy achieved a pathologic complete response in stage IIIA lung adenocarcinoma harboring RET fusion: a case report
by: Minqian Dai, et al.
Published: (2024-01-01) -
Clinical factors and major pathological response after neoadjuvant chemoimmunotherapy in potentially resectable lung squamous cell carcinoma
by: Ye Wang, et al.
Published: (2024-04-01) -
Non-invasive prediction for pathologic complete response to neoadjuvant chemoimmunotherapy in lung cancer using CT-based deep learning: a multicenter study
by: Wendong Qu, et al.
Published: (2024-03-01) -
A systematic review and meta-analysis of neoadjuvant chemoimmunotherapy in stage III non-small cell lung cancer
by: Wei Liu, et al.
Published: (2022-12-01) -
Deep learning for predicting major pathological response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer: A multicentre studyResearch in context
by: Yunlang She, et al.
Published: (2022-12-01)